<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66961">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01677039</url>
  </required_header>
  <id_info>
    <org_study_id>B4531004</org_study_id>
    <nct_id>NCT01677039</nct_id>
  </id_info>
  <brief_title>Study to Determine the Effects of Co-Administration of Alcohol on the Absorption of Oxycodone From a Proprietary Controlled-Release Formulation</brief_title>
  <official_title>An Open-label, Single-dose, Randomized, Three-way Crossover Study to Estimate the Effects of Ethanol 20% and 40% on the Bioavailability a Controlled Release Formulation of Oxycodone 20 Mg With Sequestered Naltrexone 2.4 Mg in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to test whether or not the rate and extent of absorption of oxycodone
      from a proprietary controlled-release formulation is significantly affected by
      co-administration of alcohol compared with controlled conditions (when the formulation is
      administered with water).  The primary pharmacokinetic parameters are the peak concentration
      of oxycodone (Cmax) and the overall exposure level of oxycodone as represented by the area
      under the plasma concentration-time curve (AUC).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Maximum observed oxycodone concentration in plasma (Cmax)</measure>
    <time_frame>hours after dosing</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the oxycodone concentration versus time curve (AUC)</measure>
    <time_frame>hours after dosing</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-to-peak concentration (Tmax)</measure>
    <time_frame>hours after dosing</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>half-life of drug</measure>
    <time_frame>hours after dosing</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs and adverse events</measure>
    <time_frame>hours after dosing</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test formulation administered with water</intervention_name>
    <description>single dose of 20 mg of test formulation with 240 mL of water</description>
    <arm_group_label>Treatment A</arm_group_label>
    <other_name>ALO-02 20 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test formulation administered with 20% ethanol</intervention_name>
    <description>single dose of 20 mg of test formulation with 240 mL of 20% ethanol in water</description>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>ALO-02 20 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test formulation administered with 40% ethanol</intervention_name>
    <description>single dose of 20 mg of test formulation with 240 mL of  40% ethanol</description>
    <arm_group_label>Treatment C</arm_group_label>
    <other_name>ALO-02 20 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers

          -  history of moderate alcohol consumption

          -  total body weight exceeding 64 kg

        Exclusion Criteria:

          -  history of clinically significant disease

          -  history of sleep apnea

          -  any condition affecting drug absorption

          -  pregnant or nursing female subjects

          -  history of allergy or hypersensitivity to either oxycodone or naltrexone
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4531004&amp;StudyName=Study%20to%20Determine%20the%20Effects%20of%20Co-Administration%20of%20Alcohol%20on%20the%20Absorption%20of%20Oxycodone%20from%20a%20Proprietary%20Controlled-Release%20Formul</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 10, 2012</lastchanged_date>
  <firstreceived_date>August 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <keyword>oxycodone</keyword>
  <keyword>ethanol interaction</keyword>
  <keyword>healthy volunteers</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
